Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 22 results.
User Information
Export Records
  1. 1.   CRISPR-Cas9-AAV versus lentivector transduction for genome modification of X-linked severe combined immunodeficiency hematopoietic stem cells
  2. Brault, Julie; Liu, Taylor; Liu,Siyuan; Lawson, Amanda; Choi, Uimook; Kozhushko, Nikita; Bzhilyanskaya, Vera; Pavel-Dinu, Mara; Meis, Ronald J; Eckhaus, Michael A; Burkett,Sandra; Bosticardo, Marita; Kleinstiver, Benjamin P; Notarangelo, Luigi D; Lazzarotto, Cicera R; Tsai, Shengdar Q; Wu, Xiaolin; Dahl, Gary A; Porteus, Matthew H; Malech, Harry L; De Ravin, Suk See
  3. Frontiers in Immunology. 2023, Jan 4; 13: 1067417.
  1. 2.   Complex Tumor Spheroids, a Tissue-Mimicking Tumor Model, for Drug Discovery and Precision Medicine
  2. Kaur, Gurmeet; Evans, David M.; Teicher, Beverly A.; Coussens,Nathan
  3. SLAS Discovery. 2021, Nov 12;
  1. 3.   Bioequivalence assessment of high-capacity polymeric micelle nanoformulation of paclitaxel and Abraxane (R) in rodent and non-human primate models using a stable isotope tracer assay
  2. Hwang, Duhyeong; Vinod, Natasha; Skoczen,Sarah; Ramsey, Jacob D.; Snapp,Kelsie; Montgomery, Stephanie A.; Wang, Mengzhe; Lim, Chaemin; Frank, Jonathan E.; Sokolsky-Papkov, Marina; Li, Zibo; Yuan, Hong; Kabanov, Alexander; Stern,Steve
  3. Biomaterials . 2021, Nov; 278
  1. 4.   Comparative microsomal proteomics of a model lung cancer cell line NCI-H23 reveals distinct differences between molecular profiles of 3D and 2D cultured cells
  2. Kaczmarczyk,Jan; Roberts,Rhonda; Luke,Brian; Chan,King; Van Wagoner, Carly M; Felder, Robin A; Saul, Richard G; Simona, Colantonio; Blonder,Josip
  3. Oncotarget. 2021, Sep 28; 12(20): 2022-2038.
  1. 5.   Nucleic Acid Nanoparticles at a Crossroads of Vaccines and Immunotherapies
  2. Dobrovolskaia,Marina
  3. Molecules (Basel, Switzerland). 2019, Dec; 24(24):
  1. 6.   Glypican-3-Specific Antibody Drug Conjugates Targeting Hepatocellular Carcinoma
  2. Fu, Ying; Urban, Daniel J.; Nani, Roger R.; Zhang, Yi-Fan; Li, Nan; Fu, Haiying; Shah, Hamzah; Gorka, Alexander P.; Guha, Rajarshi; Chen, Lu; Hall, Matthew D.; Schnermann,Martin; Ho, Mitchell
  3. Hepatology (Baltimore, Md.). 2019, AUG; 70(2): 563-576.
  1. 7.   Inhibition of HIV Maturation via Selective Unfolding and Cross-Linking of Gag Polyprotein by a Mercaptobenzamide Acetylator
  2. Jenkins, Lisa M. Miller; Paine, Elliott L.; Deshmukh, Lalit; Nikolayevskiy, Herman; Lyons, Gaelyn C.; Scerba, Michael T.; Rosenker, Kara George; Luecke, Hans F.; Louis, John M.; Chertova,Elena; Gorelick,Robert; Ott,David; Clore, G. Marius; Appella, Daniel H.
  3. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY. 2019, MAY 22; 141(20): 8327-8338.
  1. 8.   Nanoparticle physicochemical properties determine the activation of intracellular complement
  2. Ilinskaya, Anna N.; Shah, Ankit; Enciso, Alan E.; Chan,King; Kaczmarczyk,Jan; Blonder,Josip; Simanek, Eric E.; Dobrovolskaia,Marina
  3. Nanomedicine : nanotechnology, biology, and medicine. 2019, APR; 17: 266-275.
  1. 9.   Sterically induced conformational restriction: Discovery and preclinical evaluation of novel pyrrolo[3,2-d]pyrimidines as microtubule targeting agents
  2. Pavana, Roheeth Kumar; Shah, Khushbu; Gentile, Taylor; Dybdal-Hargreaves, Nicholas F.; Risinger, April L.; Mooberry, Susan L.; Hamel, Ernest; Gangjee, Aleem
  3. BIOORGANIC & MEDICINAL CHEMISTRY. 2018, NOV 1; 26(20): 5470-5478.
  1. 10.   Preclinical therapeutic response of residual metastatic disease is distinct from its primary tumor of origin
  2. Day, C. P.; Carter, J.; Bonomi, C.; Hollingshead, M.; Merlino, G.
  3. International Journal of Cancer. 2012, Jan; 130(1): 190-199.
  1. 11.   Specific targeting to B cells by lipid-based nanoparticles conjugated with a novel CD22-ScFv
  2. Loomis, K.; Smith, B.; Feng, Y.; Garg, H.; Yavlovich, A.; Campbell-Massa, R.; Dimitrov, D. S.; Blumenthal, R.; Xiao, X. D.; Puri, A.
  3. Experimental and Molecular Pathology. 2010, Apr; 88(2): 238-249.
  1. 12.   Scaling-up and production of therapeutic antibodies for preclinical studies
  2. Feng, Y.; Dimitrov, D. S.
  3. Methods in molecular biology (Clifton, N.J.). 2009 525: 499-508, xiii.
  1. 13.   Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution
  2. Dobrovolskaia, M. A.; Aggarwal, P.; Hall, J. B.; McNeil, S. E.
  3. Molecular Pharmaceutics. 2008 5(4): 487-495.
  1. 14.   Antitumor Efficacy Testing in Rodents
  2. Hollingshead, M. G.
  3. Journal of the National Cancer Institute. 2008 100(21 DI 10.1093/jnci/d):
  1. 15.   HER2-Specific Affibody-Conjugated Thermosensitive Liposomes (Affisomes) for Improved Delivery of Anticancer Agents
  2. Puri, A.; Kramer-Marek, G.; Campbell-Massa, R.; Yavlovich, A.; Tele, S. C.; Lee, S. B.; Clogston, J. D.; Patri, A. K.; Blumenthal, R.; Capala, J.
  3. Journal of Liposome Research. 2008 18(4): 293-307.
  1. 16.   Marine pharmacology in 2003-2004: Anti-tumour and cytotoxic compounds
  2. Mayer, A. M. S.; Gustafson, K. R.
  3. European Journal of Cancer. 2006, Sep; 42(14): 2241-2270.
  1. 17.   Precancer in mice: Animal models used to understand, prevent, and treat human precancers
  2. Cardiff, R. D.; Anver, M. R.; Boivin, G. P.; Bosenberg, M. W.; Maronpot, R. R.; Molinolo, A. A.; Nikitin, A. Y.; Rehg, J. E.; Thomas, G. V.; Russell, R. G.; Ward, J. M.
  3. Toxicologic Pathology. 2006 34(6): 699-707.
  1. 18.   In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus (HIV) chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques
  2. Ambrose, Z.; Boltz, V.; Palmer, S.; Coffin, J. M.; Hughes, S. H.; KewalRamani, V. N.
  3. Journal of Virology. 2004, DEC; 78(24): 13553-13561.
  1. 19.   Marine pharmacology in 2001-2: antitumour and cytotoxic compounds
  2. Mayer, A. M. S.; Gustafson, K. R.
  3. European Journal of Cancer. 2004, DEC; 40(18): 2676-2704.
  1. 20.   SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity. Part 2: Efficacy evaluations
  2. Alley, M. C.; Hollingshead, M. G.; Pacula-Cox, C. M.; W, W. R.; Hartley, J. A.; Howard, P. W.; Gregson, S. J.; Thurston, D. E.; Sausville, E. A.
  3. Cancer Research. 2004, SEP 15; 64(18): 6700-6706.
  1. 21.   Preclinical Evaluation of 9-Chloro-2-Methylellipticinium Acetate Alone and in Combination With Conventional Anticancer Drugs For the Treatment of Human Brain Tumor Xenografts
  2. Arguello, F.; Alexander, M. A.; Greene, J. F.; Stinson, S. F.; Jorden, J. L.; Smith, E. M.; Kalavar, N. T.; Alvord, W. G.; Klabansky, R. L.; Sausville, E. A.
  3. Journal of Cancer Research and Clinical Oncology. 1998 124(1): 19-26.
  1. 22.   Data augmentation and multimodal learning for predicting drug response in patient-derived xenografts from gene expressions and histology images
  2. Partin, Alexander; Brettin, Thomas; Zhu, Yitan; Dolezal, James M; Kochanny, Sara; Pearson, Alexander T; Shukla, Maulik; Evrard,Yvonne; Doroshow, James H; Stevens, Rick L
  3. Frontiers in Medicine. 2023 10: 1058919.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel